By employing the iMFEX nanosensor, researchers successfully monitored the dynamic fluctuations in exosomal PD-L1 expression triggered by reagents and distinguished non-small cell lung cancer patients from healthy individuals, thereby establishing the clinical applicability potential of the platform [80]. Here, CD274 is linked to non-small cell lung carcinoma.